Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts


Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10007 of 10176  at  6/18/2019 7:27:52 AM  by

Aspector


 In response to msg 10005 by  biochemyst
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

Thanks for your insights.
Do you think AMGN could acquire ANG3, even though it competes with their own Repatha? You see it as a follow-on product to Repatha, or is there need/room for both PCSK9 drugs in the market?


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1  
   Views: 281 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10008 Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA biochemyst 7 6/18/2019 10:05:54 AM
10009 Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA evernewbliss 4 6/18/2019 3:02:43 PM


Financial Market Data provided by
.
Loading...